There is a great deal of interest in the adjuvant use of Avastin for breast cancer. FDA approved Avastin on 2/27/08 for first line treatment of metastatic cancer only. It is in several studies, including: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer, NCT00528567 There are indications that adjuvant Avastin may not be effective in colon cacner where it is also being studied for adjuvant therapy. According to the results of a Phase III clinical trial, the addition of the targeted therapy Avastin® (bevacizumab) to post-surgery chemotherapy does not reduce the risk of cancer recurrence among patients with early-stage colon cancer. The current results are from a Phase III trial known as NSABP C-08. The study enrolled patients with Stage II or Stage III colon cancer. After surgical removal of the cancer, patients were assigned to receive adjuvant chemotherapy alone (mFOLFOX6) or adjuvant chemotherapy plus Avastin.
The results of the study indicate that the addition of Avastin to chemotherapy did not reduce the risk of cancer recurrence. The same may turn out to be the case for breast cancer. Full results from this study are expected to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO), which will be held May 29-June 2, 2009.